Severe Exacerbation of Asthma. Severe Exacerbation of Asthma
Conditions
Interventions
Intervention 1: Intervention group: Routine treatment regimen for moderate to severe asthma plus montelukast 5 mg orally/day. Intervention 2: Control group: Control group: Routine moderate to severe a
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 14 Years
Inclusion criteria
Inclusion criteria: Age 5 to 14 years old Hospitalized with a diagnosis of severe asthma attack Patients who have used salbutamol in the past two weeks A diagnosed history of moderate to severe persistent asthma Not taking Montelukast
Exclusion criteria
Exclusion criteria: Parents' lack of consent to participate in the study Patients who are taking phenytoin, phenobarbital, or rifampicin (due to drug interactions) The presence of any other possible diagnoses that mimic asthma symptoms There are clear contraindications for prescribing montelukast. The occurrence of dangerous side effects and drug allergies to montelukast
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of hospital stay. Timepoint: The entire length of hospital stay. Method of measurement: Hospital file.;The need for adjunctive therapies such as magnesium sulfate. Timepoint: The entire length of hospital stay. Method of measurement: Hospital file. | — |
Secondary
| Measure | Time frame |
|---|---|
| The occurrence of drug side effects including headache, nausea, diarrhea, and hives. Timepoint: The entire duration of hospitalization. Method of measurement: Taking a patient history.;Differences in response to treatment based on the type of triggering agent (infectious or non-infectious). Timepoint: The entire duration of hospitalization. Method of measurement: Taking a patient history. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Choupani
Oroumia University of Medical Sciences
Outcome results
None listed